提示: 手机请竖屏浏览!

晚期肺癌的新标准治疗
A New Standard of Care for Advanced Lung Cancer


Joan H. Schiller ... 肿瘤 • 2018.05.31
相关阅读
• 阿特珠单抗用于转移性非鳞状NSCLC的一线治疗 • 派姆单抗治疗转移性非小细胞肺癌

1995年,非小细胞肺癌协作组(Non-small Cell Lung Cancer Collaborative Group)发表了一项具有里程碑意义的荟萃分析,包括8项随机试验,这些试验对采用化疗和无治疗或最佳支持治疗作为转移性非小细胞肺癌(NSCLC)的一线治疗进行了比较1。这项荟萃分析不仅显示未经治疗的NSCLC患者结局不良(1年总生存率为5%),而且还显示以顺铂为基础的化疗可影响NSCLC的自然病程(1年总生存率为15%)。





作者信息

Joan H. Schiller, M.D.
From the Inova Schar Cancer Institute, Fairfax, VA.

 

参考文献

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.

2. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.

3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.

4. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177.

5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015;373:1627-1639.

6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015;373:123-135.

7. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016;375:1823-1833.

8. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018;378:2078-2092.

9. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med 2017;376:2415-2426.

10. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093-2104.

服务条款 | 隐私政策 | 联系我们